ProSomnus Sleep Technologies has partnered with MonitAir LLC to integrate remote patient monitoring capabilities into the treatment of obstructive sleep apnea, a move aimed at giving healthcare providers better visibility into patient health over time.
Announced Monday, the collaboration will allow clinicians who prescribe the ProSomnus RPMO₂ OSA Device to view and monitor patient data through MonitAir’s digital health platform. Consequently, providers will be able to track physiological information across multiple nights and coordinate care through a single monitoring system.
Obstructive sleep apnea (OSA) affects millions of people and causes repeated interruptions in breathing during sleep. The condition can contribute to daytime fatigue, cardiovascular problems and other health complications if left untreated.
The ProSomnus RPMO₂ OSA Device recently received U.S. Food and Drug Administration Class II clearance. The device incorporates a pulse oximeter directly into a maxillary dental overlay, allowing it to measure oxygen saturation and pulse rate while a patient sleeps.
Unlike traditional monitoring equipment, the device collects data from within the mouth during normal use. Additionally, it stores and transmits that information for review by healthcare providers.
According to ProSomnus, the technology can operate in both clinical and home settings. The company said researchers validated the device against arterial oxygen saturation measurements and demonstrated accuracy across clinically relevant oxygenation ranges.
MonitAir will provide the digital infrastructure supporting the partnership. The company’s FDA registered and HIPAA compliant platform combines remote physiologic monitoring, remote therapeutic monitoring and chronic care management tools within a unified workflow.
Read more: Sleep tech innovator ‘Kimba’ launches novel scent therapy system
Read more: SOND’s new sleep tech ear buds may be the most advanced yet
Remote monitoring recognized as useful tool
The platform aggregates information from connected devices and presents it through data visualization and compliance tracking tools. Furthermore, it allows clinicians to communicate with patients and coordinate care through a centralized system.
The companies said the integration supports a more personalized approach to sleep apnea management. OSA symptoms and physiological measurements often vary from night to night, making long term monitoring valuable for understanding treatment effectiveness.
Healthcare organizations increasingly recognize remote monitoring as a useful tool for managing chronic conditions. Meanwhile, guidance from the American Academy of Sleep Medicine, the American Medical Association and evolving policies from the Centers for Medicare & Medicaid Services acknowledge remote monitoring services as part of ongoing patient care.
“Effectively managing Obstructive Sleep Apnea requires continuous, actionable insights, not just a single snapshot in time,” said Dr Edward Mezerhane, CEO of MonitAir, LLC.
“By integrating the high fidelity data from the ProSomnus RPMO₂ OSA Device directly into MonitAir’s comprehensive monitoring platform, we are giving clinicians the longitudinal visibility they need.
Within those frameworks, providers may use remotely collected data to document patient status, engage patients through digital communication tools and coordinate treatment activities. Additionally, clinicians can review long term trends rather than relying solely on information gathered during individual appointments.
By combining an intraoral pulse oximeter with a remote monitoring platform, the ProSomnus MonitAir collaboration aims to support continuous data collection and ongoing clinical oversight for sleep apnea patients.
.
